Tom van Meerten
dr.
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
Outcomes of patients over 70 years treated with brexu-cel for R/R mantle cell lymphoma: a study from the CTIWP of EBMT
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2025019367
document
Mantle cell lymphoma (MCL) predominantly affects older adults, and treatment options for relapsed/refractory (R/R) disease remain limited. Brexucabtagene autoleucel (brexu-cel) has demonstrated high efficacy in R/R MCL, but data in older adult populations are scarce. This retrospective, real-world analysis evaluated patients aged ≥70 years with R/R MCL treated with brexu-cel and reported to the EBMT registry between 2020 and 2024. A total of 233 patients from 96 centers across 13 countries were included (median age at infusion, 74.6 years; 44% >75 years). Most had Eastern Cooperative Oncology Group...
Nicole Santoro, Jarl Edouard Mooyaart, Urban Novak, Rachel Protheroe, Francis Ayuk, Peter Dreger, Tom van Meerten, Shankara Paneesha, Robin Sanderson, Ron Ram, Michael Northend, Edouard Forcade, Anne Huynh, Ibrahim Yakoub-Agha, Jorinde Desiree Hoogenboom, Maiana Hamdan Melo Coelho, Simona Pagliuca, Florent Malard, Jürgen Kuball, Anna SuredaAli Bazarbachi, Annalisa Ruggeri, Vanderson Rocha
A Novel Hypothermic Preservation Formulation Containing SUL-138 Enables Long-Term Hypothermic Storage of Clinical-Grade CAR-T Cells
Published in: Pharmaceutics
Access to document
10.3390/pharmaceutics18040414
document
Background/Objectives: Point-of-care (PoC) manufactured fresh chimeric antigen receptor (CAR)-T cells are typically formulated in hypothermic preservation formulations (HPFs) and stored under hypothermic conditions (2-8 °C) until administered to the patient. However, in current HPFs the shelf life of fresh CAR-T cells is short (~24-36 h) due to limited CAR-T cell stability, which poses significant time constraints on manufacturing procedures and logistics. The objective of this study was to improve the stability and extend the shelf life of fresh clinical-grade CAR-T cell drug products (DPs). Methods: A novel HPF...
Aysenur Öner, Nina Nooteboom, Linette Oosting, Jos G W Kosterink, Bart G J Dekkers, Adrianus C van der Graaf, Tom van Meerten, Guido Krenning, Daniel H Swart, Robin Dennebos, Harm-Jan Lourens, Edwin Bremer, Bahez Gareb
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3
Published in: Blood
Access to document
10.1182/blood.2025029734
document
Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL) based on the ZUMA-2 cohort 1 (ClinicalTrials.gov identifier: NCT02601313) study in which brexu-cel demonstrated a 93% objective response rate (ORR) and 67% complete response (CR) rate in patients with R/R MCL and previous BTKi therapy (N = 60). Here, we report the primary results of ZUMA-2 cohort 3 (brexu-cel in patients with BTKi-naive R/R MCL). Adults received brexu-cel at 2 × 106 anti-CD19 CAR T...
Tom van Meerten, Marie José Kersten, Gloria Iacoboni, Georg Hess, Pim Mutsaers, Alejandro Martín García-Sancho, Andre Goy, Eva Giné, Brian T. Hill, Wen Kai Weng, Patrick M. Reagan, Krish Patel, Ahmed Galal, Charles Herbaux, Robin Sanderson, Edouard Forcade, Max S. Topp, Roch Houot, Dan Zheng, Wangshu ZhangJustyna Kanska, Rhine R. Shen, Rita Damico Khalid, Ioana Kloos, Martin Dreyling, Michael L. Wang
Author Correction: Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.
Published in: Nature Communications
Access to document
10.1038/s41467-026-69473-2
document
Janneke W de Boer, Kylie Keijzer, Jaap A van Doesum, Nienke A M Smit, Adrienne H Brouwers, Joyce van Sluis, Marjolijn N Lub-de Hooge, Frank R Pierik, Gerwin A Huls, Lisanne V van Dijk, Lydia Visser, Arjan Diepstra, Walter Noordzij, Simon P Williams, Alexander Ungewickell, Sjoerd G Elias, Elisabeth G E de Vries, Anne G H Niezink, Tom van Meerten
Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia
Published in: Journal of translational medicine
Access to document
10.1186/s12967-026-07701-5
document
Background: Chimeric Antigen Receptor (CAR)-T cell therapy holds considerable promise for the treatment of CD7+ T cell malignancies. However, a major challenge limiting clinical development of CD7-targeted CARs has been fratricide,a process of self-cytotoxicity caused by the shared expression of CD7 on malignant and healthy cells. Current solutions, including CD7 gene editing, intracellular retention or cell-sorting strategies, add significant complexity and cost, thereby limiting the feasibility and cost-effectiveness of this therapy. In this study, we evaluated whether fratricide can instead be overcome by tailoring standard manufacturing protocols to...
Jimena Álvarez Freile, Lena Rockstein, Rianne Kloosterman, Macarena González Corrales, Nienke Visser, Harm Jan Lourens, Orsolya Frittmann, Robin Dennebos, Nienke A M Smit, Airies Setroikomo, Marta Requesens, Nienke van Rooij, Aysenur Öner, Marco de Bruyn, Tom van Meerten, Mar Bellido, Gerwin Huls, Bahez Gareb, Edwin Bremer